Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSYRINGEStandard

NEULASTA

PEGFILGRASTIM

Standard Dose
6MG/0.6ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview NEULASTA is listed in Drugs@FDA under application 125031 (BLA).

Review priority: N/A Marketing status: Prescription Active ingredient PEGFILGRASTIM Form and strength SYRINGE - 6MG/0.6ML Sponsor AMGEN Submission history Latest submission status date: 2025-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEULASTA is listed in Drugs@FDA under application 125031 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient PEGFILGRASTIM Form and strength SYRINGE - 6MG/0.6ML Sponsor AMGEN Submission history Latest submission status date: 2025-08-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.